Harald A. Weber
Dr. Harald Weber received his medical degree from the Humboldt-University/School of Medicine (Charité) in Berlin and is trained in Internal Medicine and Oncology at hospitals in Germany and at UWCCC in Madison, Wisconsin. He was also a research fellow at the Institute of Immunology and Department of Dermatology at the Humboldt-University (Charité). Main subjects of his research were the immune-modulating effects of synthetic peptides on bone-marrow cells and the immune system in murine models and immune-compromised patients. After practicing medicine in several hospitals in Germany Dr. Weber worked at Boehringer Ingelheim in Germany as medical team leader for several early and late stage development projects. He joined Hoffmann La-Roche in Basel in 2000 and was tenured as a Clinical Scientist and Clinical Science Leader in 2003. He has been involved in the development program of Herceptin in HER2 positive early breast cancer and was the clinical lead for the development of Avastin and its approval in metastatic colorectal cancer in Europe and other countries. Until the end of 2013 he led the global development of a subcutaneous formulation of Herceptin resulting in its approval in EU in 2013. His research interests include the effects of drugs on the immune system, new targeted therapy approaches, especially for patients with breast cancer, and the clinical development of biopharmaceutical products. He is currently the strategic and medical lead for all scientific aspects related to biopharmaceuticals/biosimilars and provides medical, scientific and regulatory expertise in this field to Global Medical Affairs teams, especially in the oncology/hematology diease area.